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factor a.Pharmacologic treatments for nonalcoholic steatohepatitis (NASH) are limited. Lifestyle
interventions are believed to be effective in reducing features of NASH, although the effect of
regular exercise, independent of dietary change, is unclear. We performed a randomized
controlled trial to study the effect of exercise on hepatic triglyceride content (HTGC) and
biomarkers of fibrosis in patients with NASH.METHODS: Twenty-four patients (mean age, 52 – 14 y; body mass index, 33 – 6 kg/m2) with sedentary
lifestyles (<60 min/wk of moderate–vigorous activity) and biopsy-proven NASH were assigned
randomly to groups that exercised (n [ 12) or continued standard care (controls, n[ 12) for
12 weeks while maintaining their weight. The exercise (cycling and resistance training) was
supervised at an accredited sports center and supervised by a certified exercise specialist and
recorded 3 times per week on nonconsecutive days. We measured HTGC, body composition,
circulating markers of inflammation, fibrosis, and glucose tolerance at baseline and at 12
weeks.RESULTS: Compared with baseline, exercise significantly reduced HTGC (reduction of 16% – 24% vs an
increase of 9% – 15% for controls; P < .05), visceral fat (reduction of 22 – 33 cm2 vs an increase
of 14 – 48 cm2 for controls; P < .05), plasma triglycerides (reduction of 0.5 – 1.0 mmol/L vs an
increase of 0.3 – 0.4 mmol/L for controls; P < .05), and g-glutamyltransferase (reduction of 10 –
28 U/L–1 vs a reduction of 17 – 38 U/LL1 for controls; P < .05). There were no effects of exercise
on liver enzyme levels, metabolic parameters, circulatory markers of inflammation (levels of
interleukin 6, tumor necrosis factor-a, or C-reactive protein) and fibrosis.CONCLUSIONS: In a randomized controlled trial, 12 weeks of exercise significantly reduced HTGC, visceral fat,
and plasma triglyceride levels in patients with NASH, but did not affect circulating markers of
inflammation or fibrosis. Exercise without weight loss therefore affects some but not all factors
associated with NASH. Clinical care teams should consider exercise as part of a management
strategy of NASH, but weight management strategies should be included. Larger and longer-
term studies are required to determine the effects of exercise in patients with NASH. ISRCTN
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from simple steatosis through nonalcoholic steatohepa-
titis (NASH), fibrosis, and cirrhosis.1 Current evidence
from a large single-center serial biopsy study, supported
by a recent meta-analysis, indicates that approximately
40% of NAFLD cases will show progressive fibrosis dur-
ing a median 6.6-year follow-up evaluation.2,3 Although
the accumulation of various lipids in the liver is the pre-
requisite for NAFLD, recent evidence suggests that in-
flammatory biomarkers also could play a role in the
development of NASH.4
Currently, there are no approved pharmacologic
therapies for managing NAFLD, although a number of
promising agents are in trial.5 Lifestyle interventions,
incorporating weight loss and increased physical
activity/exercise, remain the cornerstone of NAFLD
management,6–9 however, implementation remains
difficult.10 Evidence supporting the effect of physical
activity independent of weight loss is limited, impeding
successful translation into clinical practice. Increasing
physical activity through structured exercise has shown
a significant beneficial effect on hepatic triglyceride
content (HTGC).7,11,12 To date, only 1 study has assessed
the effect of exercise in biopsy-proven NASH and re-
ported no change in HTGC or fibrosis.9 However, the
study did not include a control group and used the
percentage of hepatocytes affected to assess HTGC,
limiting sensitivity.
The primary objective of this randomized controlled
trial was to determine the effects of exercise, without
weight loss, on HTGC in adults with biopsy-confirmed
NASH. The secondary aims were to determine the ef-
fect of exercise on mediators of NASH: abdominalTable 1. Subject Characteristics
Control (n ¼ 12)
Baseline
Post-
treatment P va
Anthropometry
Age, y 51 (16) -
BMI, kg/m2 33 (5) 34 (5) .18
Weight, kg 94 (9) 95 (9) .15
VO2peak, mL/kg
-1/min-1 21 (5) -
Metabolic
ALT level, U/L-1 81 (59) 75 (52) .28
AST level, U/L-1 59 (27) 58 (30) .33
GGT level, U/L-1 113 (78) 96 (53) .08
Total cholesterol level, mmol/L 4.9 (1.3) 5.2 (1.3) .07
Triglyceride level, mmol/L 2.0 (0.9) 2.3 (1.0) .02
Platelets, 10 g/L 261 (83) 258 (75) .42
Albumin level, g/L 46.5 (2.5) 46.7 (3.3) .35
NOTE. Values are means (SD).
GGT, g-glutamyltransferase; VO2peak, aerobic capacity.
aSignificant difference in baseline vs post-intervention (P < .05).
bSignificant difference in time  treatment interaction (P < .05).adiposity, glucose control, circulating markers of
inflammation, and noninvasive markers of fibrosis.Materials and Methods
Thirty-one patients with histologically characterized
NASH (age, 59  12 y; body mass index [BMI], 35  5
kg/m2) were screened for study entry. Patients with
evidence of other liver disease or a history of excessive
alcohol consumption (alcohol intake >20 g/d for women
or >30 g/d for men) were excluded (Table 1). The study
protocol was approved by the Sunderland Research
Ethics Committee, UK, and all patients provided written
informed consent. Liver biopsy specimens were scored
histologically by 2 expert histopathologists (A.D.B. and
D.T.) according to the NASH Clinical Research Network
criteria.13 The NAFLD activity score was graded between
0 and 8, and fibrosis was staged from 0 to 4 as previously
performed14 (Table 2). Other exclusion criteria included
the following: heart or kidney disease, implanted ferrous
metal, pre-existing medical conditions preventing
participation in the exercise program, insulin-sensitizing
treatment, or dietary change over the preceding 6
months. Five patients were excluded during screening
because of abnormal electrocardiographs and 1 patient
withdrew because of claustrophobia during magnetic
resonance imaging scanning (see Consolidated Standards
of Reporting Trials diagram, Supplementary Figure 1).
Twenty-six sedentary (<60 min/wk of moderate-
vigorous activity) patients were assigned randomly us-
ing a permuted blocks method to either exercise (n ¼ 13)
or standard care (n ¼ 13) (Supplementary Figure 1).
Participant characteristics are summarized in Table 1.Exercise (n ¼ 12)
Time  treatment
interaction
lue Baseline
Post-
treatment P value P value
54 (12) -
33 (7) 33 (7) .12 .77
90 (18) 91 (18) .12 .86
25 (8)
53 (25) 52 (18) .31 .44
41 (14) 45 (12) .17 .30
66 (46) 56 (33) .05a .82
4.7 (1.4) 4.5 (1.3) .26 .20
a 2.2 (1.0) 1.7 (0.8) .09 .03b
208 (42) 214 (44) .06 .35
45.4 (3.8) 45.7 (3.4) .31 .93
Table 2. Baseline Liver Histology and NAFLD Fibrosis Score
Control (n ¼ 12) Exercise (n ¼ 12) P value
NAS 5 (2–7) 5 (3–7) .61
Steatosis 1 (1–3) 2 (1–3) .80
Inflammation 1 (0–2) 2 (1–2) .47
Ballooning 1 (0–2) 1 (1–2) .52
Fibrosis stage 3 (0–3) 3 (2–3) .28
0 1 (4%) 0 (0%)
1 2 (8%) 0 (0%)
2 3 (13%) 5 (21%)
3 6 (25%) 7 (29%)
4 0 (0%) 0 (0%)
NOTE. Baseline liver histology and fibrosis stage are shown as a median
(range) for all patients.
NAS, NAFLD activity score.
- 2016 An Exercise Study in NASH Patients: A RCT 3After an initial screening visit, patients underwent a full
medical history, physical examination, and progressive
exercise test to screen for any undiagnosed cardiac dis-
ease as previously described.12 HTGC, body composition,
fasted blood samples, including inflammatory (inter-
leukin 6 [IL6], tumor necrosis factor a [TNF-a], and high-
sensitivity C-reactive protein [hsCRP] (V-PLEX K15049D
plate; Meso-Scale, Rockville, MD; and Roche Diagnostics
Ltd, Burgess Hill, UK, respectively) and fibrosis markers
(cytokeratin-18 [CK-18] using the M30-Apoptosense
emzyme-linked immunosorbent assay kit; PEVIVA,
Bromma, Sweden),15 and a 2-hour frequently sampled
oral glucose tolerance test were measured at baseline
and at 12 weeks.12,16,17
Study Intervention
Exercise was supervised by an accredited exercise
specialist and recorded to ensure adherence 3 times per
week on nonconsecutive days for 12 weeks.18,19 The
exercise program consisted of aerobic (cycling) and
resistance training, and is detailed in Supplementary
Methods. All patients were instructed not to alter their
diet and to maintain their current weight throughout the
study.
Statistics
Sample size was calculated based on change in HTGC
from previous data in NAFLD12; an 80% power of
detecting a 10% relative difference between group
change in liver HTGC with a SD of 9.0 and a 1-sided 0.05
significance required n ¼ 11 per group. We recruited 13
per sample to allow 2 drop-outs per group. Normality
was assessed using a Kolmogorov–Smirnov test and
logarithmically transformed if not normally distributed.
Between-group differences were evaluated using an un-
paired t test and within-group differences using a paired
t test (2 way). Treatment  time interactions were
assessed using a 2-way analysis of variance. Analyses of
covariance were used to test for between-group differ-
ences in outcome variables while controlling for baseline
values. Bivariate correlations using Pearson rank corre-
lations were conducted to investigate any associations
between HTGC, body composition, triglyceride levels,
glucose control, biomarkers of inflammation, and NAFLD
fibrosis marking systems. Statistical significance was set
at a P value of less than .05. Statistical analyses were
performed using SPSS statistical analysis software
(version 19; IBM, Chicago, Illinois). All authors had ac-
cess to the study data and reviewed and approved the
final manuscript.
Results
Twenty-six patients were randomized, with 2 patients
withdrawing owing to pre-existing knee and backproblems (Supplementary Figure 1). Twenty-four pa-
tients completed the study,with all subjects in the exercise
group completing the 36-session exercise program. The
control and exercise groups were well matched (Table 1),
with no significant differences in age (51  16 vs 54 
12 y) or BMI (33 5 vs 33 7 kg/m2). Baseline histologic
scores and fibrosis staging are shown in Table 2.
Body Mass Index, Body Composition,
and Hepatic Triglyceride Content
During the study, BMI, weight, and subcutaneous fat
remained constant in both groups (Tables 1 and 3).
Visceral fat decreased by 12% in the exercise group and
increased by 7% in the control group (P < .01) (Figure 1
and Table 3). Exercise increased lean body mass by 4%
vs 0% in the control group (P < .05), and reduced fat
mass by 6% vs 0% in the control group, although the
latter was not statistically significant. Exercise produced
a 16% reduction in HTGC compared with an 8% increase
in the control group (P < .05) (Figure 1 and Table 3).
Blood Lipid and Liver Enzyme Levels
There was a time by treatment interaction for tri-
glyceride levels, with exercise eliciting a reduction of
23% vs a 13% increase in the control group (P < .05).
There was also a significant reduction of 13% in
g-glutamyltransferase after exercise (P < .05). No other
significant changes in blood biochemistry were observed
in either group (Table 1).
Metabolic Control
The exercise group showed a -17% vs -7% reduction
in fasting insulin level, and decreased homeostatic model
assessment of insulin resistance of -17% vs þ6%,
although these values did not reach statistical signifi-
cance (Table 3). There were no differences in any other
glucose control variables after the intervention in either
Table 3. Hepatic Triglyceride Content, Adipose Tissue, Body Composition, and Metabolic Control
Control (n ¼ 12) Exercise (n ¼ 12)
Time  treatment
interaction
Baseline
Post-
treatment
P
value Baseline
Post-
treatment
P
value P value
Hepatic triglyceride content, % 10 (5) 11 (5) .08 12 (9) 10 (6) .04a .02b
Visceral adipose tissue, cm2 173 (75) 187 (53) .02a 191 (86) 169 (50) .04a .01c
Subcutaneous adipose tissue, cm2 396 (124) 337 (181) .24 409 (113) 318 (158) .08 .07
Fat mass, kg 38 (9) 38 (8) .37 35 (15) 33 (15) .07 .24
Lean body mass, kg 57 (7) 57 (7) .10 56 (10) 58 (10) .01d .51
Fasting glucose, mmol/L 5.8 (1.5) 5.8 (1.8) .41 6.7 (1.7) 6.6 (1.6) .38 .80
Fasting insulin, pmol/L 98 (58) 91 (52) .18 118 (75) 99 (44) .23 .96
HOMA-IR 1.6 (1.1) 1.7 (1.0) .18 2.3 (1.4) 1.9 (0.8) .26 .53
HbA1c, mmol/mol 47 (11) 49 (15) .16 52 (14) 50 (13) .14 .13
fsOGTT, AUC 838 (191) 879 (270) .23 1016 (279) 980 (329) .20 .91
NOTE. Values are means ( SD).
AUC, area under the curve; fsOGTT, frequently sampled oral glucose tolerance test; HbA1c, glycated hemoglobin; HOMA-IR, homeostasis model of insulin
resistance.
aSignificant difference in baseline vs postintervention (P < .05).
bSignificant difference in time  treatment interaction (P < .05).
cSignificant difference in time  treatment interaction (P < .01).
dSignificant difference in baseline vs postintervention (P < .01).
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ment interaction for fasting blood glucose, fasting insulin,
glycated hemoglobin, homeostatic model assessment of
insulin resistance, or glucose area under the curve for
the frequently sampled oral glucose tolerance test were
observed (Table 3).
Circulatory Inflammation and Noninvasive
Fibrosis Markers
There was no significant time by treatment interac-
tion for exercise on circulating inflammatory biomarkers,
CK-18, hsCRP, or the noninvasive markers of fibrosis
(NAFLD fibrosis score, aspartate aminotransferase
[AST]/alanine aminotransferase [ALT] ratio, and
enhanced liver fibrosis test) (Table 4).
Correlations
HTGC was associated positively with visceral fat at
baseline and after the intervention (r¼ 0.49, P¼ .01; and
r ¼ 0.36, P ¼ .04, respectively). There was also a positive
correlation between the changes in HTGC and visceral fat
after the intervention (r ¼ 0.39, P ¼ .03). There were no
other significant correlations between HTGC, body
composition, glucose control, biomarkers of inflammation,
or fibrosis markers at baseline or postintervention.
Discussion
This RCT examined the effects of exercise, indepen-
dent of weight loss, in adults with histologically
confirmed NASH. The data show that 12 weeks ofexercise resulted in the following: (1) a 16% reduction in
liver fat, (2) a 12% reduction in visceral fat, (3) a 23%
reduction in circulating triglyceride levels, and (4) a 4%
increase in lean body mass. However, 12 weeks of
exercise had no significant effect on glucose control,
circulating markers of inflammation, liver enzyme levels,
or NAFLD activity score.
Lifestyle modification combining dietary change and
exercise produces a robust reduction in HTGC and even
reversal of inflammation with more than 10% weight
loss in people with NASH,6,8 data on exercise without
weight loss are lacking. We show that 12 weeks of ex-
ercise therapy resulted in a 16% reduction in HTGC, in-
dependent of weight loss in people with NASH. The
changes in HTGC reported here are in line with previous
reports of exercise without weight loss in people with
NAFLD11,12 and show the effectiveness of exercise in
reducing HTGC in NASH. Although consistent with earlier
reports in NAFLD, our observation contrasts with the
only other study looking specifically at exercise in NASH,
which reported an apparent stability of HTGC after 6
months of exercise.9 The difference between these
studies most likely can be explained by the greater
sensitivity of proton magnetic resonance spectroscopy
(as used in this study) vs histologic assessment of the
percentage of hepatocytes affected in the small number
of cases in the previous study and the well-controlled
design of the present study. Our HTGC data suggest
that exercise may hold therapeutic benefits for people
with NASH.
Although the reduction in HTGC with exercise is
encouraging, the changes reported here should be placed
in context of studies using a combination of weight loss
and exercise in NAFLD, which see a relative reduction of
Figure 1. Effect of 12 weeks exercise training (Exercise) or
standardcare (Control) onabsolutechanges in intrahepatic lipid
(A), visceral fat (B), and triglycerides (C) from baseline. Values
are means SE.M (n¼ 24) *, significantly different from control
(P < .05). **, significantly different from control (P < .01).
Table 4. Liver Enzyme Levels, NAFLD Activity Score, Increased
Control(n ¼ 12)
Baseline Post-treatment P valu
ALT/AST ratio 0.92 (0.44) 0.93 (0.36) .42
NAFLD fibrosis score 0.95 (1.43) 0.98 (1.53) .36
Increased liver fibrosis test 8.8 (0.9) 8.8 (1.1) .46
TNF-a, pg/mL 2.3 (0.7) 2.3 (0.7) .25
IL6, pg/mL 2.4 (4.2) 2.0 (2.7) .38
hsCRP, mg/L 2.1 (1.5) 3.1 (3.0) .48
CK-18, U/L 842 (1140) 781 (1013) .44
NOTE. Values are means ( SD).
- 2016 An Exercise Study in NASH Patients: A RCT 5between 42% and 81% in HTGC after a mean weight
reduction of 4% to 14%.7 Weight loss and exercise
yielding a 10% reduction in body weight can reverse
NASH,6,8 highlighting the summative benefits of weight
loss and exercise. Although weight loss undoubtedly is
effective in reducing HTGC, the difficulty of maintaining
weight loss in the long term is well documented.10 As
such, the optimal clinical value of exercise upon liver
health for people with NASH appears likely to be an
adjunct to caloric restriction. However, exercise without
weight loss may represent an alternative therapy for
patients who find weight loss difficult.
The mechanisms underlying the change in HTGC after
exercise in NASH reflect changes in energy balance, cir-
culatory lipids, and insulin sensitivity. Without any
change in body weight, exercise reduced visceral fat by
12%. To date, only 1 study has assessed the effects of
exercise in biopsy-proven NASH,9 however, the current
RCT assessed the effects of exercise on HTGC, metabolic
control, body composition, alongside inflammatory and
fibrosis markers in patients with NASH. Visceral fat is
reported to be linked directly with liver inflammation
and fibrosis, independent of insulin resistance and he-
patic steatosis.20 The precise mechanism of how visceral
fat applies its detrimental effects on liver metabolism
and fibrotic and inflammatory consequences remains
unclear, although an influx of fatty acids and synthesis of
cytokines and adipokines has been shown to promote
liver lipid accumulation, insulin resistance, and inflam-
mation.20,21 The present data support the close rela-
tionship between visceral fat and HTGC, with baseline
visceral fat correlating with HTGC and the change in
visceral fat with exercise correlating with the change in
HTGC.
The apparent stability in metabolic control here is
surprising given the reduction in HTGC and visceral fat,
and the close link between HTGC, hepatic insulin sensi-
tivity, and endogenous glucose production.22,23 Despite a
16% reduction in HTGC, 19 patients remained above the
clinical 5% HTGC diagnosis, suggesting that a larger
reduction in HTGC is required to improve hepatic insulin
sensitivity and glucose control significantly, as recentlyLiver Fibrosis Test, and Circulatory Cytokines/Inflammation
Exercise(n ¼ 12)
Time  treatment
interaction
e Baseline Post-treatment P value P value
0.86 (0.32) 0.92 (0.36) .10 .63
1.51 (1.00) 1.50 (1.12) .47 .80
9.4 (1.1) 9.5 (1.2) .35 .76
2.2 (0.6) 2.4 (0.7) .17 .25
1.4 (0.7) 1.7 (1.7) .44 .77
2.8 (2.4) 4.9 (4.9) .21 .71
627 (764) 441 (275) .43 .82
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glycemic control, the selective reduction of both visceral
fat and HTGC with exercise, independent of weight loss,
supports exercise as an adjunct therapy for NASH, as
previously shown in NAFLD.11,12
In this study there was a reduction in CK-18, a marker
of apoptosis and a defining pathologic feature of NASH,
known to correlate with liver damage and fibrosis.15
However, TNF-a, IL6, and hsCRP all remained stable in
the exercise group, despite changes in HTGC and visceral
fat. Although increased liver lipid is a prerequisite of
NASH,26 dysregulated cytokine metabolism plays an
important role in disease progression.4 Exercise studies
in coronary artery disease, type 2 diabetes mellitus, and
NAFLD have reported reductions in circulating cytokine
levels (IL6 and TNF-a)27,28 and CK-18,29 raising the
possibility of a protective effect of exercise. However, a
combined weight loss and exercise program in people
with NASH also showed a stability in circulatory cytokine
levels, with the exception of IL6, which was reduced.30
Importantly, circulatory inflammatory markers do not
represent inflammation inside of the liver. Because he-
patic inflammatory markers were not assessed directly,
HTGC may represent a better biomarker of free fatty acid
flux, oxidative stress, and ER stress that result in stea-
tosis and progressive liver damage.31 Although there are
clear biological links between inflammation and NASH,
further studies are required to understand how lifestyle
management may be optimized to address these.
Liver enzyme levels (ALT, AST) and noninvasive
scores of liver disease (ALT/AST ratio, NAFLD fibrosis
score, and an increased liver fibrosis test) did not change
with 12 weeks of exercise therapy. Furthermore, changes
in HTGC were not correlated with liver enzyme levels or
noninvasive scores of liver disease. Our study used liver
enzyme levels and noninvasive measures of liver disease
because follow-up biopsies to assess liver histology were
not ethically permitted. However, biopsy data show that
significant weight loss as a result of calorie restriction
and exercise improves liver histology.6,8 The lack of
change in liver enzyme levels and biomarkers of liver
disease after exercise suggest that exercise without
weight loss may be insufficient to influence liver fibrosis
directly. However, without a follow-up biopsy it is diffi-
cult to truly ascertain the impact of exercise alone on
NASH. The present data support longer and larger
studies investigating the differential and combined ef-
fects of exercise and weight loss in NASH to confirm their
effects on disease progression.
Limitations
The present study was not without limitation. Liver
fibrosis was not measured directly from biopsy after
exercise. However, because recent work has suggested
that steatosis and NASH may be more interchangeable
than previously thought2 it was ethically difficult tojustify exposing volunteers to the risk of a repeat biopsy
within such a short period of time. Although powered
sufficiently for the primary outcome, the sample size may
be insufficient to define secondary outcomes. The length
of the study, although comparable with previous exercise
studies in NAFLD, may not have been long enough in
duration to observe any improvements in histology and
circulating inflammation in NASH.Conclusions
Exercise was well tolerated and reduced HTGC,
visceral fat, and circulating triglycerides in adults with
biopsy-proven NASH, independent of weight loss, but
without any apparent impact on circulating markers of
inflammation or noninvasive scores of liver disease.
These data suggest that increased exercise in the absence
of weight loss is effective at reducing HTGC, but may be
less efficacious at ameliorating steatohepatitis over a
12-week program. Clinically, exercise has a significant
beneficial effect on HTGC and visceral fat. However, the
optimal clinical value of exercise for people with NASH
appears likely to be an adjunct to caloric restriction.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at http://dx.doi.org/10.1016/j.cgh.2016.07.031.References
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Supplementary Methods
Protocol
Twenty-six sedentary (<60 min/wk of moderate-
vigorous activity) patients were assigned randomly us-
ing a permuted blocks method with an independent
member of the research group1 to either exercise inter-
vention (n ¼ 13) or standard care (n ¼ 13)
(Supplementary Figure 1). Participant characteristics are
summarized in Table 1. After an initial screening visit,
patients underwent a full medical history, physical ex-
amination, and progressive exercise test to screen for any
undiagnosed cardiac disease as previously described.12
Body composition, HTGC and abdominal fat were
measured using air-displacement plethysmography and a
3.0 Tesla Philips Achieva magnetic resonance image
scanner (Guilford, Surrey), respectively, also as previously
described.2–6
Blood Analyses
A 75-g glucose load (Lucozade Original; Glaxo
SmithKline, Brentford, UK) was then consumed within 5
minutes and blood samples then were taken at 15, 30, 45,
60, 75, 90, and 120 minutes. Samples were analyzed for
whole-blood glucose (YSI 2300 Stat Plus-D; Yellow
Springs Instruments, Yellow Springs, OH), and plasma
insulin (Coat-A-Count Insulin RIA kit; Diagnostic Products
Corporation, CA). The area under the curve for the
resulting glucose response profile was calculated using
the trapezoidal rule7 and insulin resistance was deter-
mined using the homeostasis model of insulin resistance.8
Fasting samples also were analyzed in a Clinical Pathology
Accredited laboratory (Newcastle Upon Tyne Hospital
NHS Foundation Trust, Department of Clinical Biochem-
istry) for the following: ALT, AST, g-glutamyltransferase,
total cholesterol, triglycerides, and glycated hemoglobin.
Total cholesterol, triglycerides, ALT, AST, and g-gluta-
myltransferase were measured using a Roche Modular P
test kit, CK-18 using the M30-Apoptosense emzyme-
linked immunosorbent assay kit (PEVIVA),9 hsCRP
(Roche Diagnostics Ltd, Burgess Hill, UK), and glycated
hemoglobin were measured using a TOSOH HLC-723G7
(Tosoh Corporation, Tokyo, Japan). Plasma samples
were analyzed for circulatory inflammatory markers
using a V-PLEX K15049D plate (Meso-Scale), and serum
samples were analyzed for levels of tissue inhibitor of
matrix metalloproteinase 1, hyaluronic acid, and amino-
terminal peptide of procollagen III at an independent
Clinical Pathology Accredited laboratory (North
Middlesex University Hospital NHS Foundation Trust).
Exercise Intervention
Exercise was supervised and performed 3 times per
week on nonconsecutive days for 12 weeks, a program
we have used successfully for patients with NAFLD10
and type 2 diabetes.11 The exercise program consisted
of aerobic (cycling) and resistance training and is
detailed in the Supplementary Clinical Trial Study Pro-
tocol. The cycling included a 5-minute warm-up and 3
intervals on a fixed bike for 2 minutes with a 1-minute
rest in-between. Exercise intensity was based on the
Borg (6–20 points) rating of perceived exertion with
bike intervals corresponding to a rating of perceived
exertion of 16 to 18 (very hard).12 This was followed by
a resistance exercise circuit that comprised 5 exercises:
hip and knee extension, horizontal row, chest press,
vertical row, and knee extension (Precor, Woodinville,
WA). Patients were provided with a suitable weight for
each resistance exercise based on a rating of perceived
exertion of 14 to 16 (hard). The rating of perceived
exertion was used to guide intensity for safety, time
effectiveness, its translational use in clinical practice,
and its effectiveness at determining one repetition
maximum.13,14 Each session lasted between 45 and 60
minutes. All sessions were conducted at an accredited
sports center and supervised by a certified exercise
specialist, who recorded progress to ensure adherence
and encouraged exercise progression through adding
resistance on the bike and increasing the weights lifted
as able. This also helped to improve safety, adherence,
and the opportunity to resolve any problems. Standard
care consisted of volunteers continuing any prescription
medication and going for regular monitoring of their
condition(s) with their normal general practitioner and/
or consultant(s). After 12 weeks of exercise all follow-
up tests were performed within 24 hours of the final
exercise session.
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